Skip to main content
Enanta Logo
  • About
    • About Enanta
    • Management Team
    • Board of Directors
    • Contact Us
  • Research
    • Research
    • HBV
    • NASH
    • RSV, hMPV & SARS-CoV-2
    • Pipeline
  • Clinical Trials
  • Licensed Products
    • HCV Licensed Products
  • News
  • Careers
    • Working At Enanta
    • Careers
    • Benefits
  • Investors
    • Financial News
    • Events & Presentations
    • Stock Information
      • Stock Quote
      • Stock Chart
      • Historical Stock Quote
      • Investment Calculator
      • Analyst Coverage
    • Financials
      • Quarterly Results
      • Annual Reports
      • SEC Filings
    • Corporate Governance
      • Governance Documents
      • Executive Management
      • Board of Directors
      • Committee Composition
    • Investor Resources
      • Investor FAQs
      • Information Request Form
      • Email Alerts
      • RSS Feeds
    • Contact Us

News

  • About
    • About Enanta
    • Management Team
    • Board of Directors
    • Contact Us
  • Research
    • Research
    • HBV
    • NASH
    • RSV, hMPV & SARS-CoV-2
    • Pipeline
  • Clinical Trials
  • Licensed Products
    • HCV Licensed Products
  • News
  • Careers
    • Working At Enanta
    • Careers
    • Benefits
  • Investors
    • Financial News
    • Events & Presentations
    • Stock Information
      • Stock Quote
      • Stock Chart
      • Historical Stock Quote
      • Investment Calculator
      • Analyst Coverage
    • Financials
      • Quarterly Results
      • Annual Reports
      • SEC Filings
    • Corporate Governance
      • Governance Documents
      • Executive Management
      • Board of Directors
      • Committee Composition
    • Investor Resources
      • Investor FAQs
      • Information Request Form
      • Email Alerts
      • RSS Feeds
    • Contact Us
News Release RSS Feed (opens in new window)

Quick Links

  • Investor FAQs
  • Governance Documents
  • SEC Filings

IR Contact

Jennifer Viera

Investor Relations and Corporate Communications

Enanta Pharmaceuticals, Inc.

Phone: 617-744-3848

Email: jviera@enanta.com

Investor Alerts

To receive notifications via email, enter your email address and select at least one subscription below. After submitting your information, you will receive an email. You must click the link in the email to activate your subscription. You can sign up for additional subscriptions at any time.

* Required

*
*





 
Enter the code shown above.

Email Alert Sign Up Confirmation

  • About
  • Research
  • Licensed Products
  • News
  • Careers
  • Investors
Copyright Enanta Pharmaceuticals, Inc
  • Privacy Policy
  • Twitter Policy
  • Terms Of Use
Powered By Q4 Inc. 5.56.0.1 (opens in new window)

Follow Us

  • twitter
  • LinkedIn